HANGZHOU, China, Nov. 24 /PRNewswire/ -- Tigermed Consulting Co., Ltd., a leading Contract Research Organization (CRO) in China, announced that it has established strategic partnerships with two leading CROs, OCT in Russia and LSK in Korea respectively to integrate resources for the expansion and establishment of a global clinical trial network. This new strategic alliance spurs Tigermed to provide more extensive and comprehensive outsourcing clinical service for Multinational Pharmaceutical Corporations and Local Research Institutions in the research and development of innovative drugs.
Tigermed currently is ranked one of the largest Contract Research Organizations (CRO) in China, with a leading position in the Chinese clinical trial industry. Tigermed, staffed with a team of 100 professionals serving more than 150 local and global clients, has 15 offices in China and one office in the USA and a liaison office in Europe. The company's therapeutic strengths lie in areas such as oncology, biological vaccines, hepatitis, digestive system, cardiovascular and infectious diseases, in which Tigermed accumulated significant experience. Financed by Qiming Ventures, an internationally renowned venture capital organization, Tigermed now enters into a period of rapid expansion.
OCT, headquartered in Saint Petersburg, is a Russian CRO dedicated to clinical studies in Russia, Ukraine and other Eastern European countries. This strategic alliance with OCT facilitates Tigermed's expansion into these countries, and provides registration and clinical research services for Chinese Pharmaceutical Enterprises that have plans to enter into Eastern European markets.
LSK, headquartered in Seoul, is a leading CRO in Korea providing all stages of clinical research services in Korea, Japan, Taiwan and Malaysia. The strategic partnership with LSK enables Tigermed to extend its service capabilities into Asia Pacific. Tigermed will now be able to provide complete regulatory and clinical research services to Pharmaceutical Companies interested in the wider Asian market.
Industry insiders expect the union between leading CROs to facilitate Tigermed's expansion into the various markets and establish its reputation internationally in clinical research and product development. OCT and LSK plan to establish an international customer base through Tigermed's established profile and capabilities in developing new pharmaceutical products.
In addition its clinical research capabilities, TigerMed is recognized in the industry as a specialist for innovative Drug Services. Initial medical discoveries have been carried forward by Tigermed to the path of product development, which turns ideas into realities.
"By forming these strategic alliances, Tigermed takes the pioneering position in exploring business potential and achieving breakthroughs in global service capabilities through cross-border cooperation, which is a significant move for China's CROs. Strategic collaboration is one of our important tactics to expand global business, and this type of partnering becomes an essential part of our international strategy," comments Ms Cao Xiaochun, Vice President of Tigermed, who looks forward to establishing Tigermed as the leading CRO in Asia Pacific within three years, "Tigermed nurtures talent; and strategic partnering will allow great strides forward in the globalization of our talents, which will in the long run, fulfill the ambitions of Tigermed. Tigermed values human capital and seeks to develop this resource globally."
CONTACT: Zeng Haiyan, +86-571-8998-6792, or pr@tigermed.net